Company News

Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology

7 March 2025

LEARN MORE

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

10 September 2024

LEARN MORE

Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis

15 April 2024

LEARN MORE

Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib

20 March 2024

LEARN MORE

Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members

20 September 2023

LEARN MORE

Torqur AG's cancer drug candidate bimiralisib with promising new study results

15 May 2023

LEARN MORE

Swiss Rockets AG Welcomes Three New Key Members To The Team

18 April 2023

LEARN MORE

Swiss Rockets further strengthens the development of its phase II cancer drug candidate bimiralisib

23 January 2023

LEARN MORE

Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award

31 January 2023

LEARN MORE